| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.84B | +114.5% |
| Gross profit | ¥0.27B | — |
| Operating income | ¥-0.33B | — |
| Net income | ¥-0.34B | — |
| Gross margin | 32.3% | Net margin -40.8% |
| Revenue Q/Q | -6.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.57B | 67.7% |
| R&D | ¥0.44B | 52.6% |
| SG&A | ¥0.12B | 13.8% |
| Tax & other | ¥0.01B | 1.0% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中芯国际 ・ 特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies